 (J7 Clin Pathol 1995;48:652-657) 
or by an independent laboratory using the dye test (IgG) . Results-Compared with resolved data, the IgM assay was found to be highly specific (100%) with a cut off selected to give optimal performance with respect to both the early detection of specific IgM and the detection of persistent levels of specific IgM (sensitivity 98% Briefly, 10 g1 of patient sample (or control sera) was added to wells coated with mouse monoclonal antihuman IgM antibodies, and diluted with 200 ,l of assay reagent. The wells were incubated using an Amerlite shaker incubator for 30 minutes. During this incubation step, IgM class antibodies from the sample were captured specifically by these antihuman IgM antibodies. Unbound material was then removed by aspiration and washing; 100 gl of conjugate complex was then dispensed into each well and incubated for 30 minutes using an Amerlite shaker incubator. During this incubation step, the complex was captured by any toxoplasma specific IgM that had been bound to the well during the first incubation step. At the end of the incubation, unbound material was removed by aspiration and washing. The addition of the signal reagent then produced a luminescent signal which was related to the concentration of the bound peroxidase. Standard for Anti-Toxoplasma Serum TOXS 60). A result of less than 0-8 was interpreted as negative; a result of greater than 1-2 was interpreted as positive. A result between 0-8 and 1 2 was regarded as requiring a retest to confirm the result. A repeatedly retest result was interpreted as positive for IgG antibody to T gondii.
Sorin Biomedica ETI-ToxoK-G This is a conventional two step antiglobulin assay as described above. In this assay bound toxoplasma specific IgG is detected using an HRP labelled antihuman IgG antibody. A chromogenic substrate is then added and the intensity of the colour produced is proportional to the concentration of the bound peroxidase. This assay is quantitative, and has a working range of 0 to 150 IU/ml (World Health Organisation International Standard for AntiToxoplasma Serum TOXS 60) with a cut off set at 15 IU/ml.
High sensitivity agglutination assay This high sensitivity agglutination assay (HSA) was performed using formalin fixed tachyzoites as described by Desmonts The precision data for both the Amerlite Toxo IgG and Toxo IgM assays indicates that consistent results can be obtained across the respective assay ranges. Furthermore, the reproducibility of the assay in the retest region is such that a change in classification (from negative to positive or vice versa) will not occur.
Unlike specific IgG antibodies which typically persist for life, specific IgM antibodies begin to decline after several months, but may in some instances persist for over a year. [13] [14] [15] To ensure that a primary infection is detected as early as possible, it is important to ensure that any toxoplasma IgM assay is as sensitive as possible. However, a sensitive test may detect specific IgM relatively late after infection and therefore act as a poor indicator of recent infection. As there is no definitive reference method for the detection of toxoplasma IgM, the best measure of assay performance in terms of early detection is obtained through the measurement of samples from defined cases of recent infection or from seroconversion samples. Overall, the Amerlite Toxo IgM assay showed a high level of sensitivity, equivalent to that seen with a variety of different technologies recognised as possessing high sensitivity for the detection of recent infection. In the Amerlite Toxo IgM assay, only two of 10 samples taken from patients infected in early pregnancy remained positive six months after infection. Thus, from the limited study performed the clinical sensitivity of this assay appears to give a more useful window of IgM detection for routine screening than-for example, ISAGA, where antibody reactivity may persist for 18 months.16 Confirmation of this observation will, however, require a larger study to be performed. False positive results due to rheumatoid factor-like substances have been ascribed to IgM assays irrespective of whether they use indirect (antigen coated solid phase) or direct (IgM capture) procedures, although the phenomenon is more significant with indirect assays. '7 The results reported here indicate that this type of assay interference is not a problem with the Amerlite Toxo IgM assay and this may explain the high specificity observed in the routine screening population tested.
The dye test is regarded as the definitive test for the detection of toxoplasma specific antibody. It is, however, not specific for IgG antibodies alone and has been shown to react with IgM.'5 Additionally, the dye test measures antibodies reacting with whole viable tachyzoites, thus predominantly antibodies reactive with surface proteins. The Amerlite Toxo IgG assay is specific for IgG and uses an antigen preparation comprised of disrupted tachyzoites to coat the solid phase, hence the antibody profiles measured by the two procedures cannot be identical. To obtain a measure of clinical performance, it was therefore decided to minimise these effects by comparing results obtained with the Amerlite assay with those obtained using another commercially available enzyme immunoassay, and resolving any discrepancies using the dye test. No clear pattern of discrepant results was observed, although most samples apparently false positive by Amerlite were found to have only low levels of specific antibody, suggesting a toxoplasma infection sometime previously. This ability to detect "old" infection is crucial for determining the susceptibility of an individual to infection. A patient with a false negative result will not be retested during pregnancy leading to the possibility of an infection remaining undetected. Conversely, a patient with an initial false positive result will continue to be monitored throughout pregnancy and this may lead to a false indication of seroconversion and the associated anxieties for the patient. It is likely that the differences observed between the assays in this study are due to the type of antigen preparation used.
The Amerlite assay protocols used in this study do not generate fully quantitative results as defined by calibration against a standard curve. The Amerlite values produced by the assays are, however, directly related to the antibody concentration in the sample and can therefore be used as an aid in the interpretation of data from cases of recent infection.
This study clearly indicates that the Amerlite Toxo IgG assay (like many enzyme immunoassays) is less sensitive for the detection of seroconversion than the HSA, with a delay of approximately 10 to 15 days in pick up leading to two of the eight series remaining negative (numbers 1 and 5), although series 1 also remained negative by HSA. This lack of sensitivity can be explained by the IgG specificity of the Amerlite Toxo IgG assay as discussed earlier. Assays that measure both IgG and IgM (for example, the dye test) should detect seroconversion earlier than an IgG specific assay as following infection, IgM appears before IgG. With the exception of series 3, the detection of seroconversion using the Amerlite Toxo IgM assay was in agreement with the HSA results. As mentioned earlier, the cut off value for this assay has been selected to give an optimal window ofIgM detection for routine screening by minimising the detection of persistent low levels of IgM antibody. There is a six month gap between the first two time points in seroconversion series 3. It is considered likely that the raised Amerlite value (051 compared with a typical negative value of <0 1), although flagged negative, reflects the tail end of the IgM response, thus suggesting that an infection may have occurred soon after the first bleed was obtained. Unfortunately, this sample was not available for testing in the Amerlite Toxo IgG assay, but data from the other tests performed support this hypothesis. Generally, in order to determine the onset of infection more accurately, it may be more useful to use a combined screening programme (similar to that set up in France in 1978) utilising both IgG and IgM testing. The data presented in this report indicate that such an approach would be as sensitive as the dye test at detecting seroconversion, without the requirements for the facilities to handle live tachyzoites.
